Tech Tidbits From Around New Hampshire

NH companies attract investment and recognition ... and more
Optimized Synthetic Cholesterol

MilliporeSigma’s launches new synthetic cholesterol product, which could be used in mRNA therapeutics, including Pfizer-BioNTech Covid-19 Vaccine.

MilliporeSigma has launched a new product nine months ahead of schedule in order to meet what it says is the high demand for lipids, a key component of mRNA-based vaccines and therapeutics. The German manufacturer, which has a location in Jaffrey, NH, is manufacturing the synthetic cholesterol product in Darmstadt, Germany, though it also manufactures lipids in Schaffhausen, Switzerland and St. Louis, Missouri.  The launch of the product follows the company’s acquisition of AmpTec, a Hamburg, Germany, based mRNA contract development and manufacturing organization. MilliporeSigma is collaborating with more than 50 companies to support their efforts in the development and production of Covid-19 vaccines and treatments, providing custom lipids, as well as other critical raw materials, processing equipment and services used in mRNA drugs and vaccines manufacturing. Beginning February 2021, the company announced the extension of its strategic partnership with BioNTech to significantly accelerate the supply of urgently needed lipids and increase the quantities to be delivered toward the end of 2021. The lipids will be used for the production of the Pfizer-BioNTech Covid-19 Vaccine.

 

MediSpend, a Portsmouth-based global technology company providing best-in-class solutions for the life sciences industry, recently received a majority investment from Susquehanna Growth Equity, LLC, an entrepreneur-centric growth equity firm exclusively focused on software and information services companies. SGE’s prior investments across the broader healthcare vertical include Evive, HMP Global, iContracts, MMIT, ProviderTrust and RLDatix. Financial terms of the investment were not disclosed. MediSpend enables some of the world’s largest pharmaceutical, medical device and emerging biotech companies to compliantly manage high-risk business functions through top-rated software and client services.

 

Lexogen, a Vienna, Austria-based  biotech company focusing on RNA and complete transcriptome studies, with a subsidiary in Greenland, NH, announced it has earned ISO 9001:2015 certification from TÜV Austria CERT GmbH for its quality management system, encompassing the research, development and production of RNA analysis solutions, and the provision of bioinformatics solutions and services for RNA analysis. ISO 9001:2015 is a globally recognized quality management standard developed and published by the International Organization for Standardization (ISO), proving the ability to consistently provide high quality products and services that meet customer expectations and needs.

 

Stratham-based Position Imaging has achieved the Microsoft Gold Partner Status. Position Imaging is an omnichannel logistics fulfillment and asset tracking pioneer offering computer-vision based package tracking for simple, secure package delivery and retrieval. Along with the gold-level partner competency, Position Imaging’s iPickup Smart Package Room is now co-sell ready and available on Microsoft’s Azure Marketplace, which allows organizations to find, try, and provision applications from certified service providers. Position Imaging was previously selected into the coveted Microsoft for Startups program that provides qualified B2B tech startups with technology and sales enablement resources to help accelerate business growth.

 

A budding relationship between River Valley Community College (RVCC) and Lebanon-based Bio X Cell has matured into a unique way to help children who had been in foster care in New Hampshire fulfill a dream of attending college. A corporate gift to a scholarship fund ultimately led to a grant request to develop a pilot program to serve these individuals and has the potential to be replicated at other community colleges across the state. With an additional $5,000 donation from the biotechnology company, RVCC is designing programs, training staff and developing peer mentoring programs. All of the modeling, best practices and data are shared with DCYF and several other colleges in the Community College System of NH for possible replication. The “Bio X Cell Charitable Fund” is now in its third year and is directed with assistance from an advisory committee of employees. Bernadina Webber was the Bio X Cell employee who suggested the RVCC donation.

Categories: Technology